Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization-Reference-Cited by-同舟云学术

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

Published:2019-04-09 Issue:13 Volume:25 Page:3954-3961
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Schirripa Marta,Biason Paola,Lonardi Sara,Pella Nicoletta,Pino Maria Simona^ORCID,Urbano Federica^ORCID,Antoniotti Carlotta,Cremolini Chiara,Corallo Salvatore^ORCID,Pietrantonio Filippo,Gelsomino Fabio,Cascinu Stefano,Orlandi Armando,Munari Giada,Malapelle Umberto^ORCID,Saggio Serena,Fontanini Gabriella,Rugge Massimo,Mescoli Claudia,Lazzi Stefano,Reggiani Bonetti Luca,Lanza Giovanni^ORCID,Dei Tos Angelo Paolo,De Maglio Giovanna,Martini Maurizio,Bergamo Francesca,Zagonel Vittorina,Loupakis Fotios,Fassan Matteo^ORCID

Funder

Regione Veneto

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review;International Journal of Gastrointestinal Intervention;2024-07-31

3. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

4. Targeting the EGFR signalling pathway in metastatic colorectal cancer;The Lancet Gastroenterology & Hepatology;2024-07

5. Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies;Cancers;2024-05-10